News | November 13, 2024
Cupid Q2 FY25 income up 29.7%; PAT up 96.2%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Strengthening focus in Alzheimer's disease and neuroscience pipeline
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Subscribe To Our Newsletter & Stay Updated
